Payment overview · 2025
General Payments
$198.13
13 reported records · 7 companies
Healthcare provider profile · identity verified
Amber Moss, DO
Allopathic & Osteopathic Physicians|Family Medicine · GILLETTE, WY · NPI 1386022630
Verified facts
What the public records show
CMS Open Payments records show Amber Moss, DO received $198.13 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.30 | 40.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.91 | 16.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.04 | 15.2% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.73 | 10.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.68 | 7.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.60 | 7.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3.87 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $198.13 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.76 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.76 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.04 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $3.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 148 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
148 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 334 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 286 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 281 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 59 |
| Losartan Potassium | Losartan Potassium | 182 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 59 |
| Omeprazole | Omeprazole | 150 | 61 |
| Ozempic | Semaglutide | 148 | 39 |
| Metformin Hcl | Metformin Hcl | 145 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 56 |
| Sertraline Hcl | Sertraline Hcl | 138 | 44 |
| Furosemide | Furosemide | 129 | 60 |
| Prednisone | Prednisone | 119 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 117 | 100 |
| Gabapentin | Gabapentin | 114 | 44 |
| Trazodone Hcl | Trazodone Hcl | 105 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 50 |
| Allopurinol | Allopurinol | 87 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 29 |
| Meloxicam | Meloxicam | 84 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 46 |
| Azithromycin | Azithromycin | 78 | 69 |
| Ezetimibe | Ezetimibe | 76 | 22 |
| Famotidine | Famotidine | 74 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 24 |
| Farxiga | Dapagliflozin Propanediol | 70 | 19 |
| Glimepiride | Glimepiride | 68 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 17 |
| Montelukast Sodium | Montelukast Sodium | 57 | 24 |
| Alendronate Sodium | Alendronate Sodium | 56 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 46 |
| Potassium Chloride | Potassium Chloride | 51 | 20 |
| Alprazolam | Alprazolam | 48 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 15 |
| Metformin Hcl Er | Metformin Hcl | 44 | 17 |
| Carvedilol | Carvedilol | 43 | 15 |
| Fluconazole | Fluconazole | 43 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 39 |
| Simvastatin | Simvastatin | 43 | 14 |
| Ondansetron Odt | Ondansetron | 42 | 18 |
| Eliquis | Apixaban | 40 | 14 |
| Estradiol | Estradiol | 40 | 14 |
| Lorazepam | Lorazepam | 40 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 12 |
| Valacyclovir | Valacyclovir Hcl | 38 | 16 |
| Atenolol | Atenolol | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 15 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 14 |
| Warfarin Sodium | Warfarin Sodium | 35 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 25 |
| Finasteride | Finasteride | 31 | 12 |
| Levofloxacin | Levofloxacin | 31 | 20 |
| Ibuprofen | Ibuprofen | 29 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 13 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | 11 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 20 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $198.13 · 13 records | Novo Nordisk Inc | AREXVY, IBSRELA, INTELLIS ADAPTIVESTIM, MOUNJARO, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error